This is a secured debt investment, not an acquisition, so the primary risk for SRXH is credit risk on a pre-revenue biotech. Monitor CERo's clinical trial progress for CER-1236 and its cash burn rate, as the loan matures in ~6 weeks (Oct 15, 2026) unless extended. The secured position and IP collateral provide some downside protection, but the near-term maturity creates a catalyst for either repayment, extension, or potential restructuring.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 3 $1.56entry
- T+1 · 3mo ago −3.21%α −2.82% · $1.51
- T+5 · 2mo ago +1.92%α +3.07% · $1.59
- T+20 · 7w ago +3.21%α +4.39% · $1.61
- T+55 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SRX Global Inc. (SRXH) entered into a secured debt financing transaction with CERo Therapeutics Holdings, Inc. (CERO), acquiring a Consolidated Senior Secured Promissory Note consolidating $5.67M in prior notes and providing up to $6M in additional advances, for a maximum aggregate loan amount of $11.67M. The loan is secured by a first-priority security interest in all of CERO's assets, including its intellectual property and clinical-stage CER-1236 T-cell therapy program, as well as a pledge of 100% of the subsidiary's stock and an unconditional guaranty from the subsidiary. This is a debt investment by SRXH, not an acquisition, and represents a moderate deployment of capital into a high-risk, pre-revenue biotech company with a near-term maturity date of October 15, 2026, which can be extended by SRXH for up to four 30-day periods at its discretion.
Key Financial Metrics
Key Facts
- SRX Global acquired a senior secured promissory note from CERo Therapeutics Holdings with an aggregate maximum loan amount of $11,666,108.77.
- The note consolidates $5,666,108.77 in prior notes and provides for up to $6,000,000 in additional advances, with an initial advance of $775,665.00 funded on August 27, 2026.
- The loan matures on October 15, 2026, but SRXH can extend the maturity date for up to four consecutive 30-day periods at its discretion.
- The loan is secured by a first-priority security interest in substantially all assets of CERo Therapeutics, Inc., including key patents and the CER-1236 T-cell therapy program, plus a pledge of 100% of the subsidiary's stock and an unconditional guaranty.
- The note carries a 10% annual interest rate, increasing to 24.99% upon an event of default.
- CERo is a clinical-stage biotech with an ongoing Phase 1/1b CERTAIN-T trial for CER-1236 in hematologic malignancies; six patients have been treated with no dose-limiting toxicities observed in the most recent cohort.
Financial Impact
SRXH deployed $775,665 in initial cash and has committed up to $11.67M total in secured debt to CERo, a pre-revenue biotech. The investment yields 10% annual interest and is secured by CERo's IP and assets.
Risk Factors
- CERo is a pre-revenue clinical-stage biotech with no approved products, carrying high execution and financing risk.
- The loan matures on October 15, 2026, creating near-term liquidity pressure on CERo; if CERo cannot repay, SRXH may need to extend or exercise remedies against collateral.
- The value of the collateral (IP, clinical-stage assets) is highly uncertain and dependent on clinical trial outcomes and regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-041250 |
| Exhibit: ex10-2.htm | 0001493152-26-041250 |
| Exhibit: ex10-3.htm | 0001493152-26-041250 |
| Exhibit: ex10-4.htm | 0001493152-26-041250 |
| Exhibit: ex99-1.htm | 0001493152-26-041250 |
| Document: form8-k.htm | 0001493152-26-041250 |
| Document: 0001493152-26-041250-index-headers.html | 0001493152-26-041250 |
| Document: 0001493152-26-041250-index.html | 0001493152-26-041250 |
| Document: 0001493152-26-041250.txt | 0001493152-26-041250 |
Track record
30 reports on SRXH
4 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.11% at T+60 after the Jun 18, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 20, 20261d ago Press Release Neutral 3/10 Entry $0.8402 Now $0.8000 −4.78% settles Nov 30
- Nov 20, 20261d ago SC 13D Neutral 5/10 Entry $0.9950 Now $0.8000 −19.60% settles Nov 30
- Oct 30, 202622d ago Press Release Neutral 3/10 Entry $1.01 to $0.8116 Now $0.8000 −20.79% ▼ −19.64% −16.94% vs SPY
- Oct 7, 20266w ago 8-K Mixed 6/10 Entry $1.49 to $1.29 Now $0.8000 −46.31% ▼ −13.42% −12.44% vs SPY
- Oct 6, 20266w ago 8-K Neutral 4/10 Entry $1.49 to $1.29 Now $0.8000 −46.31% ▼ −13.42% −12.44% vs SPY
- Sep 24, 20268w ago Press Release Neutral 3/10 Entry $1.73 to $1.61 Now $0.8000 −53.76% ▼ −6.94% −6.52% vs SPY
- Sep 9, 202610w ago 8-K Neutral 3/10 Entry $1.51 to $1.60 Now $0.8000 −47.02% ▲ +5.96% +6.62% vs SPY
- Sep 2, 202611w ago 8-K Neutral 5/10 Viewing Entry $1.56 to $1.59 Now $0.8000 −48.72% ▲ +1.92% +3.07% vs SPY
- Aug 28, 202612w ago 8-K Bearish 5/10 Entry $1.68 to $1.59 Now $0.8000 +52.38% ▲ +5.65% +5.51% vs SPY
- Aug 19, 202613w ago 8-K Mixed 5/10 Entry $1.87 to $1.84 Now $0.8000 −57.22% ▼ −1.60% −1.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers